Search for: "In re Goldman Sachs Group, Inc. Securities Litigation" Results 21 - 37 of 37
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Mar 2016, 5:32 am
  See In re Biomet M2a Magnum Hip Implant Products Liability Litigation, 2013 WL 6405156, at *2 (N.D. [read post]
25 Aug 2010, 9:16 am by Kara OBrien
  Unlike in Maric, in this case no free cash flow estimates were actually provided to Goldman Sachs. [read post]
1 Aug 2012, 5:51 am by Mandelman
Gibbs, President of the Municipal Securities Group, Jefferies & Company, Inc. [read post]
24 Jan 2022, 12:58 pm by Cynthia Marcotte Stamer
Meanwhile, a recent Goldman Sachs survey shows small business owners identify finding workers as their top business challenge. [read post]
19 May 2009, 2:51 am
" All three legal departments that were selected this year (the winner, runner-up, and finalist) remained firm in their commitment to value, innovation, and diversity even in the face of adversity.Winner: The Hartford Financial Services Group Inc.Runner-Up: International Business Machines CorporationFinalist: Exelon CorporationSee below what made each of these legal departments stand out from the crowd: The Hartford Financial Services Group 2008 Revenue/Net… [read post]
8 Oct 2020, 8:56 am by Kristian Soltes
The settlements also leave nonsettling defendants Visa and MasterCard jointly and severally liable for the remainder of plaintiffs’ damages and secure cooperation from the bank defendants in the notice process and litigation,” the filing says. [read post]
23 Jul 2020, 7:22 am by Kristian Soltes
Supreme Court last month in the multilateral interchange fees, or MIFs, cases is an important milestone in the litigation saga and for competition litigation in the U.K. more generally. [read post]
Of particular note, in December, the Securities and Exchange Commission (”SEC”) adopted new proxy disclosure rules that likely will be a focal point for public company directors, as the new rules relate to disclosures regarding the composition and operation of boards of directors. [1] This memorandum is an update of our client alert covering considerations for public company directors in the current environment issued on October 15, 2009. 1. [read post]
17 Jan 2012, 5:50 pm by Robert Milligan
 At least one Georgia court has interpreted the new Act as providing courts discretion to re-write restrictive covenants to make them enforceable, rather than merely providing the authority to remove overbroad covenants. [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to… [read post]